References and Notes
<A NAME="RD11307ST-1">1</A>
Müller T.
Schneider R.
Schmidt RR.
Tetrahedron Lett.
1994,
35:
4763
<A NAME="RD11307ST-2">2</A> For a review, see:
Stachulski AV.
Jenkins GN.
Nat. Prod. Rep.
1998,
39:
173
<A NAME="RD11307ST-3">3</A> For a review, see:
Stachulski AV.
Harding JR.
Lindon JC.
Maggs JL.
Park BK.
Wilson ID.
J. Med. Chem.
2006,
49:
6931
<A NAME="RD11307ST-4">4</A> For a review, see:
Schaefer WH.
Curr. Drug Metab.
2006,
7:
873
<A NAME="RD11307ST-5A">5a</A>
de Graaf M.
Nevalainen TJ.
Scheeren HW.
Pinedo HM.
Haisma HJ.
Boven E.
Biochem. Pharmacol.
2004,
68:
2273
<A NAME="RD11307ST-5B">5b</A>
El Alaoui A.
Schmidt F.
Monneret C.
Florent J.-C.
J. Org. Chem.
2006,
71:
9628
<A NAME="RD11307ST-6">6</A>
Leenders RGG.
Ruytenbeek RR.
Damene EWP.
Schereen HW.
Synthesis
1996,
1309
<A NAME="RD11307ST-7">7</A>
Leenders RGG.
Damen EWP.
Bijsterveld EJA.
Schereen HW.
Houba PHJ.
van der Meulen-Muileman IH.
Boven E.
Haisma HJ.
Bioorg. Med. Chem.
1999,
7:
1597
<A NAME="RD11307ST-8">8</A>
Juteau H.
Gareau Y.
Labelle M.
Tetrahedron Lett.
1997,
38:
1481
<A NAME="RD11307ST-9">9</A>
Schmidt RR.
Angew. Chem., Int. Ed. Engl.
1986,
25:
212 ; Angew. Chem. 1986, 98, 213
<A NAME="RD11307ST-10">10</A>
Fehlhaber HW.
Snatzke G.
Vlahov I.
Liebigs Ann. Chem.
1987,
7:
637
<A NAME="RD11307ST-11">11</A>
General Procedure for the Synthesis of 1-β-
O
-Glucuronyl Carbamates and Carbonates: To a stirred solution of glucuronate 1 (1.5 mmol) and N-methyl-morpholine (5 equiv) in dry MeCN (15 mL) under nitrogen at 0 °C was added
a solution of either isocyanate or chloroformate (1 mmol in 2 mL of MeCN) over a period
of 1 h. The reaction mixture was then allowed to warm to r.t. and stirring was continued
for 1 h. The solvent was removed under reduced pressure and the resulting crude product
subjected to flash column chromatography.
Selected Data
Compound 2a: 1H NMR [(CD3)2SO]: δ = 7.46 (d, 2 H, J = 7.8 Hz), 7.28 (t, 2 H, J = 7.5 Hz), 7.03 (t, 1 H, J = 7.3 Hz), 5.91 (m, 1 H), 5.46 (m, 2 H), 5.37 (m, 2 H), 5.21 (d, 1 H, J = 10.4 Hz), 4.61 (d, 2 H, J = 5.6 Hz), 3.92 (d, 1 H, J = 9.2 Hz), 3.23 (m, 1 H) ppm. 13C NMR [(CD3)2SO]: δ = 168.51, 152.19, 138.87, 132.43, 129.18, 123.27, 118.77, 118.53, 95.26, 79.51,
76.11, 72.49, 71.72, 65.47.
Compound 2g: 1H NMR [(CD3)2CO]: δ = 8.93 (br s, 1 H), 7.50 (d, 2 H, J = 8.2 Hz), 7.22 (d, 2 H, J = 8.5 Hz), 5.57 (d, 1 H, J = 9.1 Hz), 4.82 (br s, 3 H), 4.01 (d, 1 H, J = 8.4 Hz), 3.68 (s, 3 H), 3.62 (m, 2 H), 3.45 (br s, 1 H), 2.42 (s, 3 H) ppm. 13C NMR [(CD3)2CO]: δ = 170.15, 153.14, 137.59, 133.66, 129.03, 120.60, 96.53, 77.58, 77.19, 73.77,
73.03, 52.92, 16.86 ppm.
Compound 3a: 1H NMR (CDCl3): δ = 7.06 (d, 2 H, J = 6.9 Hz), 6.80 (d, 2 H, J = 7.0 Hz), 5.82 (m, 1 H), 5.56 (d, 1 H, J = 6.9 Hz), 5.44 (br s, 1 H), 5.32 (d, 1 H, J = 17.0 Hz), 5.26 (d, 1 H, J = 10.4 Hz), 4.97 (br s, 1 H), 4.74 (br s, 1 H), 4.62 (d, 2 H, J = 5.8 Hz), 4.12 (d, 1 H, J = 8.7 Hz), 4.00 (m, 3 H), 3.72 (s, 3 H) ppm. 13C NMR (CDCl3): δ = 168.63, 157.53, 152.63, 144.40, 131.20, 121.88, 119.36, 114.42, 97.66, 75.43,
75.04, 71.84, 71.12, 66.69, 55.54 ppm.
Compound 3e: 1H NMR (CDCl3): δ = 5.45 (d, 1 H, J = 7.7 Hz), 5.31 (br s, 1 H), 4.75 (br s, 1 H), 4.69 (br s, 1 H), 4.08 (d, 1 H, J = 9.0 Hz), 3.98 (d, 2 H, J = 6.8 Hz), 3.81 (s, 3 H), 3.70 (m, 3 H), 2.00 (m, 1 H), 0.95 (s, 3 H), 0.93 (s, 3
H) ppm. 13C NMR (CDCl3): δ = 169.33, 153.85, 97.06, 77.04, 75.38, 74.95, 71.74, 71.08, 52.95, 27.60, 18.88
ppm.